Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

Abstract

Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events. (Funded by Merck; ClinicalTrials.gov number, NCT01739348 .).